Insmed Inc. (INSM)

24.51
1.08 4.22
NASDAQ : Health Technology
Prev Close 25.59
Open 25.35
Day Low/High 24.42 / 25.50
52 Wk Low/High 11.31 / 33.13
Volume 1.05M
Avg Volume 925.70K
Exchange NASDAQ
Shares Outstanding 87.28M
Market Cap 2.27B
EPS -4.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Insmed Announces Closing Of Public Offering Of Common Stock

Insmed Announces Closing Of Public Offering Of Common Stock

BRIDGEWATER, N.J.

Insmed Announces Pricing Of Public Offering Of Common Stock

Insmed Announces Pricing Of Public Offering Of Common Stock

BRIDGEWATER, N.J.

Insmed Announces Proposed Public Offering Of Common Stock

Insmed Announces Proposed Public Offering Of Common Stock

BRIDGEWATER, N.J.

New Phase 3 Data Show Sustainability And Durability Of Culture Conversion With ARIKAYCE® (amikacin Liposome Inhalation Suspension) In Patients With Refractory MAC Lung Disease

New Phase 3 Data Show Sustainability And Durability Of Culture Conversion With ARIKAYCE® (amikacin Liposome Inhalation Suspension) In Patients With Refractory MAC Lung Disease

--ARIKAYCE Plus Guideline-Based Therapy (GBT) Associated with Significantly Higher Rates of Sustained Culture Conversion on Therapy and Durable Culture Conversion Three Months Post-Treatment Compared with GBT Alone--

Insmed Reports First Quarter 2019 Financial Results And Provides Business Update

Insmed Reports First Quarter 2019 Financial Results And Provides Business Update

-- ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Net Product Sales $21.0 Million for the First Quarter of 2019 --

Insmed Granted Additional U.S. Patent For ARIKAYCE® (amikacin Liposome Inhalation Suspension), Strengthening Brand's Global Patent Portfolio

Insmed Granted Additional U.S. Patent For ARIKAYCE® (amikacin Liposome Inhalation Suspension), Strengthening Brand's Global Patent Portfolio

--Patent is 10th Issued in the U.S. for ARIKAYCE and Second Extending Patent Protection into 2035--

Insmed Provides Update On ARIKAYCE® (amikacin Liposome Inhalation Suspension) U.S. Launch

Insmed Provides Update On ARIKAYCE® (amikacin Liposome Inhalation Suspension) U.S. Launch

--ARIKAYCE Preliminary U.S. Net Product Sales Approximately $21.0 Million for the First Quarter of 2019--

Insmed To Showcase New ARIKAYCE® (amikacin Liposome Inhalation Suspension) And Pipeline Data At American Thoracic Society International Conference

Insmed To Showcase New ARIKAYCE® (amikacin Liposome Inhalation Suspension) And Pipeline Data At American Thoracic Society International Conference

--Sustainability and Durability Data from Phase 3 CONVERT Study of ARIKAYCE to be Presented in Late-Breaking Oral Session--

Insmed Announces Management Changes

Insmed Announces Management Changes

BRIDGEWATER, N.J.

Trading Roku Stock as Downgrades Sap Its Run to New Highs

Trading Roku Stock as Downgrades Sap Its Run to New Highs

Roku was hit with a pair of downgrades on Wednesday

Insmed Reports Fourth Quarter And Full Year 2018 Financial Results And Provides Business Update

Insmed Reports Fourth Quarter And Full Year 2018 Financial Results And Provides Business Update

--ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Net Product Sales of $9.2 Million for the Fourth Quarter and Full Year 2018--

INSM: Insiders Vs. Shorts

INSM: Insiders Vs. Shorts

The most recent short interest data was recently released for the 01/15/2019 settlement date, and Insmed Inc is one of the most shorted stocks of the Russell 3000, based on 6.40 "days to cover" versus the median component at 4.81. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Insmed Provides Update On ARIKAYCE® (amikacin Liposome Inhalation Suspension) U.S. Launch And Outlines Strategic Priorities For 2019

Insmed Provides Update On ARIKAYCE® (amikacin Liposome Inhalation Suspension) U.S. Launch And Outlines Strategic Priorities For 2019

-ARIKAYCE Preliminary Unaudited U.S. Net Product Sales Approximately $9.2 Million for the Fourth Quarter of 2018-

First Week Of INSM August 16th Options Trading

First Week Of INSM August 16th Options Trading

Investors in Insmed Inc saw new options become available this week, for the August 16th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 225 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Insmed Is Now Oversold (INSM)

Insmed Is Now Oversold (INSM)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

INSM: Insiders Vs. Shorts

INSM: Insiders Vs. Shorts

The most recent short interest data was recently released for the 10/15/2018 settlement date, and Insmed Inc is one of the most shorted stocks of the Russell 3000, based on 6.15 "days to cover" versus the median component at 4.82. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

First Week Of May 2019 Options Trading For Insmed (INSM)

First Week Of May 2019 Options Trading For Insmed (INSM)

Investors in Insmed Inc saw new options begin trading this week, for the May 2019 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Notable Two Hundred Day Moving Average Cross - INSM

Notable Two Hundred Day Moving Average Cross - INSM

In trading on Friday, shares of Insmed Inc crossed below their 200 day moving average of $27.16, changing hands as low as $26.70 per share. Insmed Inc shares are currently trading off about 5.4% on the day.

First Week of INSM November 16th Options Trading

First Week of INSM November 16th Options Trading

Investors in Insmed Inc saw new options begin trading this week, for the November 16th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 232 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

TheStreet Quant Rating: D (Sell)